Trodelvy Dosage and Administration

 Note: It is not advisable to substitute Trodelvy injection for or use with other medicinal products that are known for containing irinotecan or its active metabolite SN-38.



Proposed Dosage of Trodelvy:

The proposed dosage of Trodelvy is 10 mg/kg. The dosage needs to be administered as an intravenous infusion once a week on the 1st & 8th Days of 21-day treatment cycles. Continue treatment with trodelvy 180 mg until the disease progresses or has unacceptable adverse reactions.

Avoid administering Trodelvy at doses of more than 10 mg/kg. The medicine Trodelvy is for intravenous use only. This medicinal product is not for use as an intravenous push or bolus. 

Initial Infusion: Administer trodelvy infusion over three hours. Assess respective patients throughout the infusion and a minimum of 30 minutes following the initial dose for signs-symptoms of infusion-related reactions. 

Subsequent Infusions: Administer trodelvy infusion over 60-120 minutes in case previous infusions were tolerated. Assess respective patients throughout the infusion and for at least 30 minutes after infusion.

Premedication:

Before each dose of Trodelvy injection, premedication to prevent infusion reactions and chemo-induced vomiting and nausea is recommended. 

  • Patients should be premedicated with antipyretics, H1 & H2 blockers before each infusion, and corticosteroids may be considered for all those who had earlier infusion reactions.
  • The respective patients should be premedicated with a 2 or 3-medicine combination regimen.

Reference: https://www.trodelvy.com/

Comments

Post a Comment

Popular posts from this blog

Buy Trodelvy sacituzumab govitecan-hziy in India

  Trodelvy Overview: Trodelvy is widely prescribed by Oncologists for the treatment of patients with HR+/HER2- Metastatic Breast Cancer, Metastatic Triple-Negative Breast Cancer (mTNBC), and Metastatic Urothelial Cancer (mUC). It is considered a promising treatment option for those who are not ideal candidates for some conventional therapies. Developed by Immunomedics, Trodelvy 180 mg and Trodelvy 200 mg are two available commercial strengths. Worldwide, Trodelvy is promoted and facilitated by Gilead Sciences. Trodelvy is first approved on 22 April 2020. It is given by intravenous (IV) infusion by a health specialist. The medication received its (European Medicines Agency) EMA approval in October 2021. Trodelvy 180 mg and 200 mg injections are yet to be approved in India. The cost of Trodelvy in India usually depends on international factors. Buy Trodelvy from a Reliable Source: Many suppliers who are not authorized to handle or supply life-saving medicines such as Trodelvy found to b
Read more

Trodelvy: All about the drug

Image
Indication and Usage The medicine Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate drug, which is used in the treatment of adults suffering from locally advanced or metastatic triple-negative breast (mTNBC) cancer, HR+/HER2- metastatic breast cancer, and locally advanced or metastatic urothelial cancer (mUC). It is used when it is not possible to remove cancer with surgery. Trodelvy  comes in the form of single-dose vials in 180 mg for intravenous infusion. Dosage Its dosage is based on body weight, and the recommended dosage is 10 mg/kg administered intravenously once weekly on the first day and eighth day of a repeating 21-day cycle. Administration First infusion: The drug is infused in the body for 3 hours, and during the infusion, the patient is observed for any adverse reaction caused by the infusion. After 30 minutes of infusion, observation should be done again to check for any post-infusion reaction. Subsequent Infusion: If the drug is tolerated in t
Read more

What is Non-Small Cell Lung Cancer? What are the stages of NSCLC?

Image
NSCLC, the most common form of lung cancer. It occurs when the healthy cells in the lung change and start growing in an abnormal way, forming a specific mass addressed as tumor, lesion, or nodule. A tumor may develop anywhere in the lung and could be cancerous or benign. A cancerous tumor mainly is malignant, means, it has potential in order to spread to the rest part of the body. A benign tumor is the tumor that can grow but can not spread.  Non-Small Cell Lung Cancer (NSCLC) occurs in the epithelial cells. Doctors can also describe this form of Cancer (NSCLC) based on the type of the epithelial cell where the cancer usually starts.  Adenocarcinoma starts in cells that produce mucus.  Squamous carcinoma basically developed in the cells that line the airways.  Large cell carcinoma usually begins in the cells other than the two types which are described above.  It’s necessary for healthcare providers to distinguish between lung cancer that begins in the squamous cells from lung cancer
Read more